Overview

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept
Vaccines